Dopamine D3 receptor selective ligands with varying intrinsic efficacies at adenylyl cyclase inhibition and mitogenic signaling pathways

Synapse

Volumn 64, Issue 3, 2010, Pages 251-266

  Taylor, Michelle ^a   Grundt, Peter ^b   Griffin, Suzy A ^a   Newman, Amy Hauck ^b   Luedtke, Robert R ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

D2 like dopamine receptors; D3 receptors; D3 selective compounds; Dopamine receptors; Functional selectivity; Intrinsic efficacy

Indexed keywords

1 PHENYLPIPERAZINE DERIVATIVE; ADENYLATE CYCLASE; ADENYLATE CYCLASE INHIBITOR; BENZOTHIOPHENE DERIVATIVE; CJB 090; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR STIMULATING AGENT; N [4 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]BUT 2 ENYL] 4 (PYRIDIN 3 YL)BENZAMIDE; N [4 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]BUT 2 ENYL]BENZO[B]THIOPHENE 2 CARBOXAMIDE; N [4 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]BUT 2 ENYL]BENZOFURAN 2 CARBOXAMIDE; N [4 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]BUTYL] 4 (PYRIDIN 3 YL)BENZAMIDE; N [4 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]BUTYL]BENZO[B]THIOPHENE 2 CARBOXAMIDE; N [4 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]BUTYL]BENZOFURAN 2 CARBOXAMIDE; N [4 [4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL]BUT 2 ENYL] 4 (PYRIDIN 2 YL)BENZAMIDE; N [4 [4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL]BUT 2 ENYL] 4 (PYRIDIN 3 YL)BENZAMIDE; N [4 [4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL]BUT 2 ENYL]BENZO[B]THIOPHENE 2 CARBOXAMIDE; N [4 [4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL]BUT 2 ENYL]BENZOFURAN 2 CARBOXAMIDE; N [4 [4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL]BUTYL] 4 (PYRIDIN 2 YL)BENZAMIDE; N [4 [4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL]BUTYL] 4 (PYRIDIN 3 YL)BENZAMIDE; N [4 [4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL]BUTYL]BENZO[B]THIOPHENE 2 CARBOXAMIDE; N [4 [4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL]BUTYL]BENZOFURAN 2 CARBOXAMIDE; PARTIAL AGONIST; PG 01030; PG 01032; PG 01037; PG 01041; PG 01042; PG 01055; PG 01059; PG 582; PG 586; PG 838; PG 841; PG 844; PG 845; PG 848; PG 849; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MITOGENESIS; PARTIAL AGONISM; PRIORITY JOURNAL; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION;

ADENYLATE CYCLASE; CELL LINE; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; MITOSIS; PIPERAZINES; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SIGNAL TRANSDUCTION;

EID: 73449120727     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20725     Document Type: Article

References (66)

1. Bhattacharya S, Hall SE, Li H, Vaidehi N. 2008a. Ligand-stabilized conformational states of human β2 adrenergic receptor: Insight into G-protein-coupled receptor activation. Biophys J 94:2027-2042.
2. Bhattacharya S, Hall SE, Vaidehi N. 2008b. Agonist-induced conformational changes in bovine rhodopsin: Insight into activation of G-protein-coupled receptors. J Mol Biol 382:539-555.
3. Boeckler F, Gmeiner P. 2006. The structural evolution of dopamine D3 receptor ligands: Structure-activity relationships and selected neuropharmacological aspects. Pharmacol Ther 112:281-333.
4. 3 receptors in the nucleus accumbens. Pharmacol Biochem Behav 67:161-168.
5. Cenci MA. 2007. Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci 30:236-243.
6. Cheng YC, Prusoff WH. 1973. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
7. Chu W, Tu Z, McElveen E, Xu J, Taylor M, Luedtke RR, Mach RH. 2005. Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem 13:77-87.
8. Clarke WP. 2005. What's for lunch at the conformational cafeteria? Mol Pharmacol 67:1819-1821.
9. Clarke WP, Bond RA. 1998. The elusive nature of intrinsic efficacy. Trends Pharmacol Sci 19:270-276.
10. Cohen BE, Pralle A, Yao X, Swaminath G, Gandhi CS, Jan YN, Kobilka BK, Isacoff EY, Jan LY. 2005. A fluorescent probe designed for studying protein conformational change. Proc Natl Acad Sci USA 102:965-970.
11. Cunnah D, Besser M. 1991. Management of prolactinomas. Clin Endocrinol (Oxford) 34:231-235.
12. Fiorentini C, Busi C, Gorruso E, Gotti C, Spano P, Missale C. 2008. Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Mol Pharmacol 74:59-69.
13. Gay EA, Urban JD, Nichols DE, Oxford GS, Mailman RB. 2004. Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: Evidence for induction of ligand-specific receptor states. Mol Pharmacol 66:97-105.
14. 2 dopamine receptor agonists differentially modulate isolation-induced social-emotional reactivity in mice. Behav Brain Res 114:107-117.
15. Ghanouni P, Gryczynski Z, Steenhuis JJ, Lee TW, Farrensi DL, Lakowicz JR, Kobilka BK. 2001. Functionally different agonists induce distinct conformations in the G protein coupling domain of the β2 adrenergic receptor. J Biol Chem 276:24433-24436.
16. Gilbert JG, Newman AH, Gardner EL, Ashby CR Jr, Heidbreder CA, Pak AC, Peng XQ, Xi ZX. 2005. Acute administration of SB-277011A. NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: Role of dopamine D3 receptors. Synapse 57:17-28.
17. Grossfield A, Pitman MC, Feller SE, Soubias O, Gawrisch K. 2008. Internal hydration increases during activation of the G-protein-coupled receptor rhodopsin. J Mol Biol 381:478-486.
18. Grundt P, Carlson EE, Cao J, Bennett CJ, McElveen E, Taylor M, Luedtke RR, Hauck-Newman A. 2005. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl} arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. J Med Chem 48:839-848.
19. Grundt P, Prevatt KM, Cao J, Taylor M, Floresca CZ, Choi J-K, Jenkins BG, Luedtke RR, Newman AH. 2007. Heterocyclic analogues of N-{4-[4-(2,3- dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: Potential substance abuse therapeutic agents. J Med Chem 50:4135-4146.
20. Herve D, Le Moine C, Corvol JC, Belluscio L, Ledent C, Fienberg AA, Jaber M, Studler JM, Girault JA. 2001. Galpha(olf) levels are regulated by receptor usage and control dopamine and adenosine action in the striatum. J Neurosci 21:4390-4399.
21. Huff RM, Chio CL, Lajiness ME, Goodman LV. 1998. Signal transduction pathways modulated by D2-like dopamine receptors. Adv Pharmacol 42:454-457.
22. Jardemark K, Wadenberg ML, Grillner P, Svensson TH. 2002. Dopamine D3 and D4 receptor antagonists in the treatment of schizophrenia. Curr Opin Invest Drugs 3:101-105.
23. Joyce JN. 2001. Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol Ther 90: 231-259.
24. Kapur S, Mamo D. 2003. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 7:1081-1090.
25. Kenakin T, Onaran O. 2002. The ligand paradox between affinity and efficacy: Can you be there and not make a difference? Trends Pharmacol Sci 23:275-280.
26. Kenakin T. 2003. Ligand-selective receptor conformations revisited: The promise and the problem. Trends Pharmacol Sci 24:346-354.
27. Korczyn AD. 2003. Dopaminergic drugs in development for Parkinson's disease. Adv Neurol 91:267-271.
28. Kumar R, Riddle LR, Griffin SA, Chu W, Vangvervong S, Neisewander J, Mach RH, Luedtke RR. 2009a. Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa dependent abnormal involuntary movements in rats. Neuropharmacology 56:956-969.
29. Kumar R, Riddle LR, Griffin SA, Grundt P, Newman AH, Luedtke RR. 2009b. Evaluation of the D3 dopamine receptor selective antagonist PG01037 on L-dopa dependent abnormal involuntary movements in rats. Neuropharmacology 56:944-955.
30. Kuzhikandathil EV, Yu W, Oxford GS. 1998. Human dopamine D3 and D2L receptors couple to inward rectifier potassium channels in mammalian cell lines. Mol Cell Neurosci 12:390-402.
31. Kuzhikandathil EV, Westrich L, Bakhos S, Pasuit TJ. 2004. Identification and characterization of novel properties of the human D3 dopamine receptor. Mol Cell Neurosci 26:144-155.
32. Lee T, Seeman P, Rajput A, Farley IJ, Hornykiewicz O. 1978. Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature 273:59-61.
33. Luedtke RR, Mach RH. 2003. Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders. Curr Pharm Des 9:643-671.
34. 125I-IABN, a novel azabicyclononane benzamide selective for D2-like dopamine receptors. Synapse 38:438-449.
35. Magar ME. 1972. Data analysis in biochemistry and biophysics. New York: Academic Press. p 93.
36. Mailman RB, Gay EA. 2004. Novel mechanisms of drug action: Functional selectivity at D-2 dopamine receptors (a lesson for drug discovery). Med Chem Res 13:115-126.
37. Marcellino D, Ferré S, Casadó V, Cortés A, Le Foll B, Mazzola C, Drago F, Saur O, Stark H, Soriano A, Barnes C, Goldberg SR, Lluis C, Fuxe K, Franco R. 2008. Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. J Biol Chem 283:26016-26025.
38. Martelle JL, Claytor R, Ross JT, Reboussin BA, Newman AH, Nader MA. 2007. Effects of two novel D3-selective compounds. NGB 2904 [N-(4-(4-(2,3- dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2-carboxamide] and CJB 090 [N-(4-(4-(2,3-dichlorophenyl) piperazin-1-yl)butyl)-4-(pyridin-2-yl) benzamide], on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. J Pharmacol Exp Ther 321:573-582.
39. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. 1998. Dopamine receptors: From structure to function. Physiol Rev 78:189-225.
40. Nader MA, Green KL, Luedtke RR, Mach RH. 1999. The effects of benzamide analogues on cocaine self-administration in rhesus monkeys. Psychopharmacology 147:143-152.
41. Neve K, Seamans JK, Trantham-Davidson H. 2004. Dopamine signaling. J Recept Signal Transduct Res 24:165-205.
42. 3 receptor antagonists. Bioorg Med Chem Lett 13:2179-2183.
43. Newman AH, Grundt P, Nader MA. 2005. Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J Med Chem 48:3663-3679.
44. Newman AH, Grundt P, Cyriac G, Deschamps JR, Taylor M, Kumar R, Ho D, Luedtke RR. 2009. N-(4-(4-(2,3-Dichloro- or 2-methoxyphenyl) piperazin-1-yl)-butyl)-heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists. J Med Chem (in press).
45. Nieoullon A. 2002. Dopamine and the regulation of cognition and attention. Prog Neurobiol 67:53-83.
46. Pilon C, Levesque D, Dimitriadou V, Griffon N, Martres MP, Schwartz JC, Sokoloff P. 1994. Functional coupling of the human dopamine D3 receptor in a transfected NG 108-15 neuroblastomaglioma hybrid cell line. Eur J Pharmacol 268:129-139.
47. 3 receptor subtype. J Med Chem 44:3175-3186.
48. Robinson SW, Caron MG. 1997. Selective inhibition of adenylyl cyclase type V by the dopamine D3 receptor. Mol Pharmacol 52:508-514.
49. Saloman Y, Londos C, Rodbell M. 1974. A highly sensitive adenylate cyclase assay. Anal Biochem 58:541-548.
50. Sealfon SC, Olanow CW. 2000. Dopamine receptors: From structure to behavior. Trends Neurosci 23:S34-S40.
51. Senogles SE. 2003. D2s dopamine receptor mediates phospholipase D and antiproliferation. Mol Cell Endocrinol 209:61-69.
52. Shimizu H, Daly JW, Creveling CR. 1969. A radioisotopic method for measuring the formation of adenosine 3′,5′-cyclic monophosphate in incubated slices of brain. J Neurochem 16: 1609-1619.
53. Sibley DR, Monsma FJ Jr, Shen Y. 1993. Molecular neurobiology of dopaminergic receptors. Int Rev Neurobiol 35:391-415.
54. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. 1990. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146-151.
55. Spiller K, Xi ZX, Peng XQ, Newman AH, Ashby CR Jr, Heidbreder C, Gaál J, Gardner EL. 2008. The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats. Psychopharmacol (Berl) 196:533-542.
56. Su Y-F, Cubeddu LX, Perkins JP. 1976. Regulation of adenosine 3′-5′-monophosphate content of human astrocytoma cells: Desensitization to catechoamine and prostaglandins. J. Cyclic Nucleotide Res 2:257-285.
57. Swaminath G, Deupi X, Lee TW, Zhu W, Thian FS, Kobilka TS, Kobilka B. 2005. Probing the β2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J Biol Chem 280:22165-22171.
58. Uhl GR, Vandenbergh DJ, Rodriguez LA, Miner L, Takahashi N. 1998. Dopaminergic genes and substance abuse. Adv Pharmacol 42:1024-1032.
59. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB. 2007. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13.
60. Valant C, Gregory KJ, Hall NE, Scammells PJ, Lew MJ, Sexton PM, Christopoulos A. 2008. A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J Biol Chem 283:29312-29321.
61. Vallone D, Picetti R, Borrelli E. 2000. Structure and function of dopamine receptors. Neurosci Biobehav Rev 24:125-132.
62. Vangveravong S, McElveen E, Taylor M, Griffin SA, Luedtke RR, Mach RH. 2006. Identification and pharmacologic characterization of D2 dopamine receptor selective antagonists. Bioorgan Med Chem 14:815-825.
63. Volkow ND, Fowler JS, Wang GJ. 2002. Role of dopamine in drug reinforcement and addiction in humans: Results from imaging studies. Behav Pharmacol 13:355-366.
64. Witkin JM, Dijkstra D, Levant B, Akunne HC, Zapata A, Peters S, Shannon HE, Gasior M. 2004. Protection against cocaine toxicity in mice by the dopamine D3/D2 agonist R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3- b]-1,4-oxazin-9-ol [(+)-PD 128,907]. J Pharmacol Exp Ther 308:957-964.
65. Xi ZX, Newman AH, Gilbert JG, Pak AC, Peng XQ, Ashby CR Jr, Gitajn L, Gardner EL. 2006. The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology 31:1393-1405.
66. Zapata A, Kivell B, Han Y, Javitch JA, Bolan EA, Kuraguntla D, Jaligam V, Oz M, Jayanthi LD, Samuvel DJ, Ramamoorthy S, Shippenberg TS. 2007. Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors. J Biol Chem 282:35842-35854.